M. David Ullman

Biosynthesis of sphingomyelin from Eryrtro-ceramides and phosphatidylcholine by a microsomal cholinephosphotransferase

Mouse liver microsomes were shown to be active in the synthesis of sphingomyelin from ceramide and phosphatidylcholine in a reaction independent of CDPcholine. The conversion was not inhibited by calcium chelating reagents, and no evidence for the involvement of phospholipase C activity in the transformation could be adduced. Activity was also demonstrated in monkey liver and heart microsomes. Mouse brain microsomes produced a sphingomyelin analogue, tentatively identified as ceramide phosphorylethanolamine, but not sphingomyelin. Both [14C]ceramide and [G-14]phosphatidylethanolamine were precursors of the brain product, while phosphatidylcholine was inactive. Progress in the partial characterization of the liver enzyme is also described.

Fabry disease: detection of heterozygotes by examination of glycolipids in urinary sediment.

Fabry disease is an X-linked sphingolipid disorder that is manifest clinically as a disease of nerves, kidneys, and blood vessels. Precise identification of Fabry heterozygotes is essential for genetic counseling. Heterozygote detection by enzyme assay does not consistently distinguish them from unaffected females. We describe a method for Fabry heterozygote detection, based on quantitation of urinary sediment glycolipids by high-performance liquid chromatography. In specimens from 12 Fabry heterozygotes, the total glycolipid fraction was increased (10 to 100-fold) and trihexosyl ceramide (CTH) was 2-to 70-fold times normal. Digalactosyl ceramide (Digal-Cer), which is normally present in trace amounts in urine, was also increased. The ratio of CTH and Digal-Cer to hydroxy fatty acid glucosyl ceramide was increased and seemed to be characteristic of Fabry disease. This method provides rapid and accurate detection of Fabry heterozygotes.

A high performance liquid chromatography method for the analysis of glycosphingolipids using galactose oxidase/NaB3H4 labeling of intact cells and synaptosomes

The major objective of this study was to combine an HPLC method with a galactose oxidase/NaB3H4 labeling method to allow both a chemical quantitation of individual glycolipids and analysis of their 3H labeling. Neutral glycolipids in whole cells were oxidized with galactose oxidase, and the resultant aldehydes were radiolabeled by reduction with tritiated sodium borohydride. Gangliosides, oxidized with galactose oxidase, either were reduced while in the native state in the whole cell or were first extracted and then reduced. Tritiated glycolipids were perbenzoylated and separated by HPLC. Ultraviolet detection of the derivatives was at 230 nm. Incorporated radioactivity was determined either by collecting fractions from the HPLC separation and counting on a liquid scintillation spectrometer or with a flow-through counter. The order of the derivatization and reduction is critical. Reduction of glycolipids prior to derivatization yielded sharp uv and radioactive peaks. Perbenzoylation of the oxidized glycolipids prior to reduction yielded multiple uv peaks, a noisy baseline, and broad radioactive peaks which did not always have a corresponding uv peak. The labeled neutral glycolipids were stable at -40 degrees C for at least 14 days, and gangliosides were stable at -15 degrees C for at least 14 days. When samples were stored at 20 degrees C there was a time-dependent decrease in the glycolipid/internal standard uv peak area ratio for GbOse4 and GbOse3 apparent by 28 days after perbenzoylation. The distribution of radiolabel among peaks showed no change with time or temperature. We adapted the technique to allow 3H labeling of glycolipids from monolayers of cultured glioma cells and from mouse brain synaptosomes.(ABSTRACT TRUNCATED AT 250 WORDS)

Biochemical studies in a patient with subacute neuropathic Gaucher disease without visceral glucosylceramide storage.

Summary: Autopsy samples were obtained from a 12.5-year-old girl who died with a neurologic disorder consisting of myoclonus, myoclonic epilepsy, spasticity, strabismus, and mild mental retardation but no hepatosplenomegaly. Studies in leukocytes, cultured skin fibroblasts, brain, liver, and spleen of this patient revealed glucosylceramide β-glucosidase (EC 3.2.1.45, glucocerebrosidase) activity about 10% of controls, and well in the range found in samples from Gaucher disease patients. Extraction of the lipids from liver and spleen with chloroform-methanol (2:1) did not show accumulation of glucosylceramide or other lipid. Examination of the lipids in brain by high performance liquid chomatography revealed the presence of glucosylceramide, which is not found in brain samples from controls. Pathologic examination of the liver and spleen revealed no evidence of Gaucher disease. The brain showed many degenerative lesions and loss of neurons. There was no complementation of glucocerebrosidase activity when the cells from this patient were hybridized with cells from patients with Type 1 or Type 2 Gaucher disease. The reason for the lack of glucosylceramide storage in the liver and spleen has not been determined.

Ethanol disordering of GM1-enriched Short-Sleep synaptosomal plasma membranes

The Long-Sleep (LS) and Short-Sleep (SS) mouse synaptosomal plasma membranes differ in ethanol sensitivity at superficial membrane regions, which corresponds with the behavioral response of the mice to ethanol hypnosis. The only significant difference between these synaptosomal plasma membranes is the synaptosomal monosialoganglioside (GM1) content, LS > SS. Here, GM1 was examined as a parameter for increasing membrane sensitivity to ethanol effects in the ethanol-resistant SS membranes. Synaptosomal plasma membranes from SS mice were allowed to incorporate exogenous GM1. Membrane order was then studied at the surface, intermediate, and interior regions of the membranes by delayed Fourier transform proton NMR in the presence and absence of perdeuterated ethanol. Differences in membrane order were observed in all three membrane regions with increasing perdeuterated ethanol concentrations depending on the synaptosomal GM1 content.

Auditory discrimination reversal learning and assessment of behavioral teratogenesis in rats

Qualitative auditory discrimination procedures were used to evaluate discrimination acquisition and reversal learning in rats. Twelve adult rats prenatally exposed to ethanol (ETOH) and 12 unexposed isocaloric controls (CON) were given training with a positively reinforced successive discrimination procedure. Most ETOH subjects were impaired relative to CON subjects on accuracy during early training sessions and the number of sessions required to meet an 80% accuracy criterion. Some ETOH subjects were also impaired on the rate of learning over a series of repeated discrimination reversals. Individual differences in reversal learning rates varied more widely with ETOH subjects than with CON subjects. Our results indicate that the auditory discrimination procedures may find application in assessments of behavioral teratogenesis.

Ceramide composition of whole brain synaptosomal gangliosides from mice genetically bred for divergent ethanol sensitivities

A comparison of the two major ceramide molecular species (d18:1-C18:0 and d20:1-C18:0) of synaptosomal gangliosides GM1, GD1a+GT1a, GD1b, GT1b, revealed a difference between the ceramide composition of ethanol-sensitive LS and ethanol-insensitive SS whole brain synaptosomal gangliosides. In all comparisons, the ratio of the two major molecular species, (d18:1-C18:0/d20:1-C18:0) was less for LS than for SS mice.

Chapter 11 High Performance Liquid Chromatography of Glycosphingolipids in Brain Disease

Publisher Summary This chapter presents a high pressure liquid chromatography (HPLC) procedure that provides the necessary sensitivity, resolution, and reproducibility to permit the determination of glucocerebroside levels in specific brain regions and to correlate the findings with the neuropathology. The microanalytical HPLC procedure for glucocerebroside permits such analyses on very small (a few mg wet weight) quantities of specific brain regions. Nine separate brain regions from types 2 and 3 Gauchers disease are analyzed by HPLC of their perbenzoylated glucocerebrosides. In both types, the greatest glucocerebroside accumulation, when compared t o controls, is found in the occipital cortex, with lesser amounts in the temporal and frontal areas. The cerebellar cortex, corpus striatum, and thalmus of the Gaucher brains mildly increases levels of glucocerebroside, especially when the values are expressed as a percentage of the total non-hydroxyl fatty acid cerebrosides. The type-2 brain stem structures also shows as light elevation of glucocerebroside over controls when the data is again expressed as the percentage of the total nonhydroxy fatty acid cerebrosides. The histopathological abnormalities in the type-2 Gaucher brain correlate with elevated tissue glucocerebroside levels. Type-3 Gaucher brain shows no pathological changes but the glucocerebroside accumulation is similar to that seen in type 2 brain.